CORAL SPRINGS, FL--(Marketwired - Jun 20, 2013) - Nutra Pharma Corporation (
"This radio test represents the first broad exposure to our Nyloxin brand," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "New Vitality is a powerhouse in direct sales and we are privileged to be working with them as they create awareness for our products," he continued. "Radio advertising has already begun as test ads have been running in major markets across the US over the past week. We believe that the consumer response will be positive, which will translate into sales growth for the products and the Company," concluded Mr. Deitsch.
Nyloxin™ is a homeopathic drug that utilizes proteins from cobra venom to relieve pain and inflammation. An analgesic that began gaining U.S. attention in 1936, cobra venom's effects in minute doses have been shown by researchers to be superior to that of morphine, a highly addictive opiate. The product is available in an easy-to-use oral spray for treating: lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, as well as a topical gel for treating: repetitive stress, arthritis and joint pain. Nyloxin™ is also available in Extra Strength formulations.
Additional benefits to Nyloxin™ include:
- All Natural
"We're excited to be working with Nutra Pharma," commented Jonathan Flicker, CEO of New Vitality. "We believe that Nyloxin represents a wonderful opportunity for us as well as the potential to partner with Nutra Pharma for other products down the road," he concluded.
For the past 16 years New Vitality (www.newvitality.com) has helped people live longer and look younger by marketing and selling vitamins, health supplements, and personal care products. Customers learn about their products from advertisements which use celebrities, sport athletes and doctors to promote them on over 2000 radio and television stations nationwide. New Vitality's catalog contains over 150 items which range from energy supplements to fruit and vegetable supplements to colon cleanses and products for men's health.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com and www.Nyloxin.net
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The radio testing of Nyloxin should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
- Health Care Industry
- Human Immunodeficiency Virus
Nutra Pharma Corp.